Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 2/20 | 0.58 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.58 |
| ▸ | CDK2 | P24941 | 2/20 | 0.58 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.55 |
| ▸ | TCF7L2 | Q9NQB0 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.53 |
| ▸ | RAD52 | P43351 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | PDE5A | O76074 | 2/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.50 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.50 |
| ▸ | GRK6 | P43250 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3108288 | 0.91 | CCNE2 (0.54) | CCNE2CCNE1CDK2CTNNB1TCF7L2 | |
| SCHEMBL3125240 | 0.86 | CTNNB1 (0.55) | CCNE2CCNE1CDK2CTNNB1TCF7L2 | |
| SCHEMBL2590386 | 0.85 | EGFR (0.70) | CTNNB1TCF7L2KMT2AMEN1EGFR | |
| SCHEMBL23747981 | 0.85 | SLC2A1 (0.66) | KMT2ASLC2A1RAD52POLBAPP | |
| SCHEMBL3114944 | 0.84 | CTNNB1 (0.56) | CCNE2CCNE1CDK2CTNNB1TCF7L2 | |
| SCHEMBL27221084 | 0.83 | CCNE2 (0.71) | CCNE2CCNE1CDK2KDM4EBCDIN3D | |
| SCHEMBL3120956 | 0.82 | CTNNB1 (0.51) | CCNE2CCNE1CDK2CTNNB1TCF7L2 | |
| SCHEMBL3115014 | 0.80 | PDE5A (0.52) | CTNNB1TCF7L2EGFRSLC2A1APP | |
| SCHEMBL3108883 | 0.79 | MEN1 (0.60) | CCNE2CCNE1CDK2CTNNB1TCF7L2 | |
| SCHEMBL3119451 | 0.79 | CTNNB1 (0.54) | CTNNB1TCF7L2SLC2A1APPACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | claimed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | CCNE2 901/4885CCNE1 692/4885CDK2 154/4885 |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | CCNE2 542/4885CCNE1 478/4885CDK2 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.